Zoetis (ZTS) Stock Rated Overweight as Key Franchises Remain Strong Amid Competition

Zoetis Inc. (NYSE:ZTS) ranks among the best medical stocks to buy according to analysts. With a price target of $210, Piper Sandler reaffirmed its Overweight rating on Zoetis Inc. (NYSE:ZTS) on July 2. According to the firm’s analysis, Zoetis’ 2025 guidance is unlikely to be negatively impacted by rising competition in its two largest franchises, dermatology and broad-spectrum parasiticides.

Zoetis (ZTS) Stock Rated Overweight as Key Franchises Remain Strong Amid Competition

According to Piper Sandler, although Elanco’s Credelio Quattro launch was successful, the new product has largely contributed to market expansion rather than capturing a sizable portion of Zoetis’ market.

Based on the strength of its key businesses, Piper Sandler believes Zoetis Inc. (NYSE:ZTS) might still surpass revenue projections even if Librela, one of its products, may experience softness.

Global animal health provider Zoetis Inc. (NYSE:ZTS) focuses on delivering high-quality medications, vaccines, diagnostic tools, genetic testing, and services.

While we acknowledge the potential of ZTS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZTS and that has 100x upside potential, check out our report about this cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.